World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
100
Citations
33320
World Ranking
732
National Ranking
27

Medicine

D-Index
100
Citations
33320
World Ranking
8330
National Ranking
326

Sjoerd H. van der Burg publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Sjoerd H. van der Burg sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 68 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 310 publications — 66th percentile

66% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

Sjoerd H. van der Burg D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Sjoerd H. van der Burg sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 162 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 100 D-Index — 86th percentile

86% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Overview

Sjoerd H. van der Burg is affiliated with Leiden University Medical Center in the Netherlands. Their research primarily focuses on medicine, with substantial contributions to immunology and microbiology. Within these broader fields, the scientist has explored oncology, immunology, epidemiology, molecular biology, and genetics.

Their work addresses several main topics: immunotherapy and immune responses, cancer immunotherapy and biomarkers, CAR-T cell therapy research, cervical cancer and HPV research, immune cell function and interaction, immune cells in cancer, and pancreatic and hepatic oncology research.

Recent notable publications include:

  • Therapeutic cancer vaccines, 2021, Nature Reviews. Cancer
  • The NKG2A-HLA-E Axis as a Novel Checkpoint in the Tumor Microenvironment, 2020, Clinical Cancer Research
  • CD39 Identifies the CD4+ Tumor-Specific T-cell Population in Human Cancer, 2020, Cancer Immunology Research
  • Vulvar cancer subclassification by HPV and p53 status results in three clinically distinct subtypes, 2020, Gynecologic Oncology
  • Strong vaccine responses during chemotherapy are associated with prolonged cancer survival, 2020, Science Translational Medicine

Their frequent co-authors include:

  • Marij J.P. Welters
  • Thorbald van Hall
  • Els M.E. Verdegaal
  • Saskia J. Santegoets
  • Noel F.C.C. de Miranda

Most of their research has been published in the following venues:

  • Journal for ImmunoTherapy of Cancer
  • Journal of Clinical Oncology
  • Clinical Cancer Research
  • Cancer Immunology Research
  • Cancer Immunology Immunotherapy

Best Publications

  • Vaccination against HPV-16 Oncoproteins for Vulvar Intraepithelial Neoplasia

    Gemma G Kenter;Marij J P Welters;A Rob P M Valentijn;Margriet J G Lowik

  • Therapeutic cancer vaccines

    Cornelis J.M. Melief;Thorbald van Hall;Ramon Arens;Ferry Ossendorp

  • Actively personalized vaccination trial for newly diagnosed glioblastoma

    Norbert Hilf;Sabrina Kuttruff-Coqui;Katrin Frenzel;Valesca Bukur

  • Vaccines for established cancer: overcoming the challenges posed by immune evasion.

    Sjoerd H. van der Burg;Ramon Arens;Ferry Ossendorp;Thorbald van Hall

  • High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4 + T cells in human melanoma

    Carsten Linnemann;Marit M van Buuren;Laura Bies;Els M E Verdegaal

  • Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines

    Cornelis J.M. Melief;Sjoerd H. van der Burg

  • Comprehensive control of human papillomavirus infections and related diseases.

    F. Xavier Bosch;Thomas R. Broker;David Forman;Anna Barbara Moscicki

  • A key role for mitochondrial gatekeeper pyruvate dehydrogenase in oncogene-induced senescence

    Joanna Kaplon;Liang Zheng;Katrin Meissl;Barbara Chaneton

  • Established Human Papillomavirus Type 16-Expressing Tumors Are Effectively Eradicated Following Vaccination with Long Peptides

    Sander Zwaveling;Sandra C. Ferreira Mota;Jan Nouta;Mark Johnson

  • Classification of current anticancer immunotherapies

    Lorenzo Galluzzi;Erika Vacchelli;José Manuel Bravo-San Pedro;Aitziber Buqué

  • Identification and manipulation of tumor associated macrophages in human cancers

    Moniek Heusinkveld;Sjoerd H van der Burg

  • High Number of Intraepithelial CD8+ Tumor-Infiltrating Lymphocytes Is Associated with the Absence of Lymph Node Metastases in Patients with Large Early-Stage Cervical Cancer

    Sytse J. Piersma;Ekaterina S. Jordanova;Mariëtte I.E. van Poelgeest;Kitty M.C. Kwappenberg

  • Neoantigen landscape dynamics during human melanoma–T cell interactions

    Els M. E. Verdegaal;Noel F. C. C. de Miranda;Marten Visser;Tom Harryvan

  • Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine.

    Marij J P Welters;Gemma G Kenter;Sytse J Piersma;Annelies P G Vloon

  • Combining Immune Checkpoint Blockade and Tumor-Specific Vaccine for Patients With Incurable Human Papillomavirus 16-Related Cancer: A Phase 2 Clinical Trial.

    Erminia Massarelli;William William;Faye Johnson;Merrill Kies

  • Phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high-risk human papillomavirus 16 in end-stage cervical cancer patients shows low toxicity and robust immunogenicity

    Gemma G Kenter;Marij J P Welters;A Rob P M Valentijn;Margriet J G Lowik

  • Anti-CTLA-4 therapy broadens the melanoma-reactive CD8+ T cell response.

    Pia Kvistborg;Daisy Philips;Sander Kelderman;Lois Hageman

  • Human Papillomavirus Type 16-Positive Cervical Cancer Is Associated with Impaired CD4+ T-Cell Immunity against Early Antigens E2 and E6

    Annemieke de Jong;Mariëtte I. E. van Poelgeest;Jeanette M. van der Hulst;Jan Wouter Drijfhout

  • Chemotherapy alters monocyte differentiation to favor generation of cancer-supporting M2 macrophages in the tumor microenvironment

    Eveline M. Dijkgraaf;Moniek Heusinkveld;Bart Tummers;Lisa T.C. Vogelpoel

  • M2 macrophages induced by prostaglandin E2 and IL-6 from cervical carcinoma are switched to activated M1 macrophages by CD4+ Th1 cells.

    Moniek Heusinkveld;Peggy J. de Vos van Steenwijk;Renske Goedemans;Tamara H. Ramwadhdoebe

  • High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4(+) T cells in human melanoma (vol 21, pg 81, 2015)

    Carsten Linnemann;Marit M. van Buuren;Laura Bies;Els M. E. Verdegaal

Frequent Co-Authors

Cornelis J. M. Melief
Cornelis J. M. Melief ISA Pharmaceuticals (Netherlands)
Marij J. P. Welters
Marij J. P. Welters Leiden University Medical Center
Rienk Offringa
Rienk Offringa German Cancer Research Center
Thorbald van Hall
Thorbald van Hall Leiden University Medical Center
Gemma G. Kenter
Gemma G. Kenter Vrije Universiteit Amsterdam
Jan W. Drijfhout
Jan W. Drijfhout Leiden University Medical Center
Gert Jan Fleuren
Gert Jan Fleuren Leiden University Medical Center
Ferry Ossendorp
Ferry Ossendorp Leiden University Medical Center
Kees L. M. C. Franken
Kees L. M. C. Franken Leiden University Medical Center
Hans W. Nijman
Hans W. Nijman University Medical Center Groningen

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in building a career that intersects with immunology, pursuing advanced nursing degrees is a popular pathway. Many professionals start by exploring online nursing programs for non nurses, which offer accessible entry points into the healthcare field without prior experience.

Once in nursing, accelerated options become critical for career advancement. The best accelerated nurse practitioner programs enable students to complete their degrees faster, allowing for a quicker transition to advanced practice roles such as Nurse Practitioners (NPs).

Specializing further, many choose to transition from a Family Nurse Practitioner (FNP) role to more acute and specialized care fields. Guidance on how to shift focus from an fnp to acnp role can be invaluable for professionals aiming to work with critically ill patients, where immunology knowledge is often essential.

Compensation also plays a key role in career decisions. Salary data such as the doctor of nursing practice salary helps prospective students and practitioners understand earning potentials across various states, informing both educational investments and career planning.

Best Scientists Citing Sjoerd H. van der Burg

Trending Scientists

Recently Published Articles